Malta - English - Medicines Authority

panpharma z.i. du clairay, 35133 luitre, france - dexamethasone sodium, phosphate - solution for injection - dexamethasone sodium phosphate 6 mg - corticosteroids for systemic use

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

hameln pharma gmbh - dexamethasone sodium phosphate 4,37 mg/ml - eq. dexamethasone 4 mg/ml - solution for injection - 4 mg/ml - dexamethasone sodium phosphate 4.37 mg/ml - dexamethasone

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

hameln pharma gmbh - dexamethasone sodium phosphate 4,37 mg/ml - eq. dexamethasone 4 mg/ml - solution for injection - 4 mg/ml - dexamethasone sodium phosphate 4.37 mg/ml - dexamethasone

United States - English - NLM (National Library of Medicine)

general injectables and vaccines, inc. - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone phosphate 10 mg in 1 ml - a. by intravenous or intramuscular injection when oral therapy is not feasible: 1. endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. congenital adrenal hyperplasia. nonsuppurative thyroiditis. hypercalcemia associated with cancer. 2. rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode o

United States - English - NLM (National Library of Medicine)

bimeda, inc. - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 3 mg in 1 ml - indications and usage: dexamethasone sodium phosphate injection is indicated as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses. contraindications: do not use in viral infections. except when used for emergency therapy, dexamethasone sodium phosphate is contraindicated in animals with tuberculosis and chronic nephritis. existence of congestive heart failure, osteoporosis and diabetes are relative contraindications. in the presence of infection appropriate antibacterial agents should also be administered and should be continued for at least 3 days after discontinuance of the hormone and disappearance of all signs of infection.

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - dexamethasone sodium phosphate - solution for injection/infusion - 4/1 milligram(s)/millilitre - glucocorticoids; dexamethasone

Canada - English - Health Canada

sterimax inc - dexamethasone phosphate (dexamethasone sodium phosphate) - solution - 4mg - dexamethasone phosphate (dexamethasone sodium phosphate) 4mg - adrenals

Canada - English - Health Canada

sandoz canada incorporated - dexamethasone phosphate (dexamethasone sodium phosphate) - solution - 4mg - dexamethasone phosphate (dexamethasone sodium phosphate) 4mg - adrenals

Canada - English - Health Canada

sandoz canada incorporated - dexamethasone phosphate (dexamethasone sodium phosphate) - solution - 10mg - dexamethasone phosphate (dexamethasone sodium phosphate) 10mg - adrenals

New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml - solution for injection - 4 mg/ml - active: dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml excipient: citric acid monohydrate creatinin sodium citrate sodium hydroxide water for injection - replacement therapy - adrenocortical insufficiency dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy. it should be supplemented with salt and or a mineralocorticoid. when so supplemented dexamethasone is indicated in: · acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy. relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available. primary and secondary adrenocortical insufficiency.